Product Information

TEKTURNA 300 MG TABLET is a brand product labeled by LXO US Inc., priced at $15.0945 per EA under NDC 70839030030. Its NADAC has been published 485 times since May 10, 2017.

FDA first approved this application on Mar 5, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TEKTURNA 300 MG TABLET

aliskiren hemifumarate
$15.0945per EA

Strength

300 mg/1

Manufacturer

LXO US Inc.

NDC

70839030030

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

1/6/2026

Active Ingredients

ALISKIREN HEMIFUMARATE

Approval Type

New Drug (NDA)

FDA Application

NDA021985

FDA Approved

3/5/2007

TE Code

AB

On Market Since

3/5/2007

Pharmacological Classes

Renin Inhibitor
Renin Inhibitors

Price Statistics

The NADAC for TEKTURNA 300 MG TABLET has been published 485 times since May 10, 2017, and over the history we have for it it has risen 126.3%. The table below summarizes its recorded NADAC range and movement.

Current price$15.0945 per EA
All-time high$15.0945 (Aug 19, 2026)
All-time low$6.6303 (Jun 21, 2017)
52-week high$15.0945
52-week low$13.8480
Median price$10.7609
Average price$10.4811
Largest weekly change+15.5% (Nov 14, 2018)
Weeks tracked485
Tracking sinceMay 10, 2017

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

+9.0%

3Y

+28.7%

5Y

+52.9%

All

+126.3%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 62% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 62%

1 alternative • Same active ingredient

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of TEKTURNA 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for TEKTURNA 300 MG TABLET, manufactured by LXO US Inc., is $15.0945 per EA (NDC 70839030030), effective Aug 19, 2026.

How has the price of TEKTURNA 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for TEKTURNA 300 MG TABLET has risen 126.3%. It has been tracked across 485 weekly CMS publications since May 10, 2017.

What are the highest and lowest recorded NADAC prices for TEKTURNA 300 MG TABLET?

Since May 10, 2017, the NADAC for TEKTURNA 300 MG TABLET has ranged from a low of $6.6303 (Jun 21, 2017) to a high of $15.0945 (Aug 19, 2026), with a median of $10.7609 per EA.

Are there cheaper alternatives to TEKTURNA 300 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALISKIREN 300 MG TABLET, is $5.7183 per EA — about 62% below TEKTURNA 300 MG TABLET.

Who manufactures TEKTURNA 300 MG TABLET?

TEKTURNA 300 MG TABLET (NDC 70839030030) is labeled by LXO US Inc., and CMS classifies it as a brand product.